GLP-1s

News

The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.

Sales & Marketing

Will your launch strategy work once it has finally left the meeting room and met the competition?

Patients

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

News

In a handful of strongly-worded warning letters, the FDA is cracking down on sales of unapproved peptides - even if they're labelled for research.

News

Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.

Patients

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.